AstraZeneca – The Science Advisory Board
The Science Advisory Board
Acute SARS-CoV-2 infection elicits distinct antibody, T-cell responses
February 1, 2021 — An analysis of antibody and T-cell responses during the entire timeline of SARS-CoV-2 infection reveals the different ways the immune system responds to the virus in the early phases of COVID-19 disease. The results, published in Cell Reports on January 21, suggest that T-cell responses may be important for controlling infection while antibodies provide longer protection.
Protein biosensors show promise for SARS-CoV-2 testing
February 1, 2021 — Scientists have developed biosensors to detect SARS-CoV-2 proteins and antibodies in simulated nasal fluids and human sera, according to a study published in Nature on January 27. The approach promises to be less costly and time-consuming than current COVID-19 testing methods.
SARS-CoV-2 mutation doesn’t affect viral spread, but may limit therapies
January 29, 2021 — As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a specific receptor-binding motif mutation on viral fitness, clinical outcomes, and resistance to therapeutic antibodies. The findings of the study were published on January 28 in Cell.
Global evidence suggests COVID-19 could be seasonal
January 28, 2021 — As the world enters year two of the COVID-19 pandemic, new research suggests that seasonality, including temperature and location, could be a factor in the spread of infections with the SARS-CoV-2 virus, according to an analysis published in Evolutionary Bioinformatics on January 26.
Not all genome editing tools are equal: CRISPR vs. TALEN
January 27, 2021 — In recent years, a number of novel genome editing tools have emerged, although not all of these tools are equal in terms of efficiency and accuracy, according to a new study published in Nature Communications on January 27. The study observed different DNA search proteins to identify the specific ways that they find target sequences in the genome.
Novel microscopy method unlocks clues to nanomedicine interactions
January 25, 2021 — A new mixed microscopy method has led to a better understanding of the interactions of proteins in the body with nanoparticles used for biotherapeutic applications. The findings, published in Nature Communications on January 25, suggest nonuniform interactions and errors that may occur in existing analytical techniques.
Which states are safest from COVID-19?
January 22, 2021 — Safety during the COVID-19 pandemic is a priority to getting back to normal activities such as work and shopping. As more individuals get vaccinated, more states will lift COVID-19-related restrictions.
Designer DNA therapies shown to effectively target cancer stem cells
January 21, 2021 — Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human myeloma, according to preclinical study data published in Cell Stem Cell on January 20. The results of the study have prompted the clinical investigation of a therapeutic candidate for the treatment of multiple myeloma.
Can antibodies to seasonal coronaviruses protect against SARS-CoV-2?
January 20, 2021 — COVID-19 is not the world’s first exposure to a coronavirus. With at least six previous exposures to various types of coronaviruses, researchers are exploring if antibodies created during earlier infection with coronaviruses can help to fight off SARS-CoV-2 infection. The findings of the study were published in Cell Reports Medicine on January 19.